As employers roll back coverage and insurers drop weight-loss indications, newly published five-year data reveals that GLP-1 receptor agonists do not immediately pay for themselves through offsetting medical savings. While clinical trials confirm profound cardiovascular and metabolic benefits, the economic reality forces a hard look at short-term healthcare budgets.
In Plain English: The Clinical Takeaway
- Mechanism of Action: GLP-1 (glucagon-like peptide-1) receptor agonists mimic natural gut hormones to stimulate insulin secretion, slow gastric emptying, and signal satiety to the brain.
- The Economic Reality: Comprehensive multi-state data shows that other medical spending increases by about 22 cents for every dollar spent on a GLP-1 drug before rebates, failing to generate immediate cost offsets.
- Cardiovascular Efficacy: Large-scale trials demonstrate that semaglutide cuts the combined rate of heart attacks, strokes, and cardiovascular deaths by 20% in high-risk populations.
Corporate Retrenchment and Commercial Coverage Rollbacks
Employer sentiment regarding anti-obesity medications has shifted. In a Business Group on Health survey of major employers, coverage of these drugs for obesity fell from 72% last year to 60% this year. Starbucks ended coverage for weight loss in October. Cigna dropped the indication for its employees on July 1st.
The impact of these policy reversals is stark. In Massachusetts, 112,000 fewer people with commercial insurance utilized a GLP-1 for weight loss in early 2026 compared to 2025, representing a 52% drop. A spokesperson for the Massachusetts Health Policy Commission noted that some of the 112,000 fewer people with commercial insurance coverage for GLP-1s now pay cash, at roughly $4,200 to $5,400 annually. Vanderbilt health policy professor Stacie Dusetzina estimates individual cash prices for the injections at $350 to $450 a month.
Amid broader retrenchment, Walmart chief people officer Donna Morris announced a shift for employees ahead of open enrollment. Starting in 2027, the company will cover certain GLP-1 medications—specifically Ozempic and Mounjaro—at no cost for type 2 diabetes management, requiring prior authorization. However, the plan continues to exclude coverage when these agents are prescribed solely for weight loss.
What Five Years of Real-World Insurance Data Reveal
The widespread scaling back of coverage is largely driven by empirical cost data. Economists at Indiana University, the University of Wisconsin, and the University of Southern California tracked 288,907 individuals with job-based insurance for five years following the initiation of a GLP-1 therapy. Most of these patients initiated older regimens between 2017 and 2019.
The analysis demonstrated that other medical spending increased by approximately 22 cents for every dollar spent on the drug prior to rebates. Daniel Sacks, one of the study’s authors, noted that accounting for rebates makes that number larger, because rebates shrink the drug’s cost to patients while leaving downstream medical utilization untouched. For semaglutide—the active pharmaceutical ingredient in Ozempic and Wegovy—other medical spending neither clearly rose nor fell over a two-year evaluation window. Sacks observed that it will require several more years of longitudinal observation to determine how tirzepatide, utilized in Mounjaro and Zepbound, compares economically.
Independent investigations corroborate these findings. Three separate evaluations identified no net short-term cost savings. Jonathan Zhang of Duke University, co-author of one such evaluation, stated that the only analyses projecting actual savings rely on simulations looking out a decade or more into the future.
| Drug & Active Ingredient | Primary Indication & Trial Findings | Commercial & Institutional Trends |
|---|---|---|
| Semaglutide (Ozempic, Wegovy) |
Cut combined heart attacks, strokes, and cardiovascular deaths by 20% in a trial of 17,604 adults with cardiovascular disease and excess weight but no diabetes. | Commercial coverage dropping; Massachusetts saw a 52% drop in commercial users in early 2026. |
| Tirzepatide (Mounjaro, Zepbound) |
In a three-year trial of adults with obesity and prediabetes, 1.3% on tirzepatide developed type 2 diabetes versus 13.3% on placebo. | Walmart covering for diabetes at zero cost starting in 2027; excluded from weight-loss plans. |
| Medicare Bridge Program (Wegovy, Zepbound, Foundayo) |
Offers eligible enrollees access for $50 a month through a limited federal program ending December 31, 2027. | Approximately 1.1 million enrollees signed up. |
Diverging Federal Strategies and the Medicare Bridge
While commercial employers pull back, federal policy has moved in the opposite direction. Since July, eligible Medicare enrollees can get Wegovy, Zepbound, or Lilly’s new pill, Foundayo, for $50 a month via the GLP-1 Bridge program. Under this framework, pharmaceutical manufacturers supply the agents to Medicare at $245 monthly. Chris Klomp, chief counselor at the Department of Health and Human Services, reported that approximately 1.1 million beneficiaries have enrolled.
CMS Administrator Mehmet Oz explained the rationale for the program, noting that at a $50 monthly price point, “all the downstream costs that would have been incurred no longer happen.” When the Congressional Budget Office examined permanent Medicare coverage in 2024, it projected $35 billion in added federal spending over a nine-year horizon. A separate study focusing on veterans, whose average age hovered around 65, identified no cost offsets.
The disparity in pricing is stark. Lilly sells Zepbound directly to employers for $449 a month. Jenny Goins of the National Alliance of Healthcare Purchaser Coalitions pointed out that this price “doesn’t appear to be much lower” than what many employers were already paying after rebates.
Abrupt cessation of these medications requires medical oversight, as clinical trials show that patients who discontinue semaglutide regained roughly two-thirds of lost weight within a year, accompanied by a return of elevated blood pressure and glycemic markers.
